TORONTO, June 26, 2018 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), a Canadian integrated medical cannabis company with its core operations in Colombia, announced today the appointment of Chris Naprawa as President, effective immediately. Mr. Naprawa, who will report to Alvaro Torres, CEO, will lead Khiron's capital markets activities, including outreach to existing and potential shareholders in Canada and internationally. This appointment is expected to increase the Company's visibility amongst institutional investors and provides greater depth of management expertise in corporate finance, investor engagement, and mergers and acquisitions.
Mr. Alvaro Torres, CEO of Khiron, stated, "Mr. Naprawa is a proven leader who brings outstanding execution strength to the Khiron team. His rare combination of skill sets, both as a capital markets professional and developer of growth companies, positions us with the ability to further focus our business activities. On behalf of our management team and board, I welcome Mr. Naprawa to our team."
Mr. Chris Naprawa, President of Khiron, stated, "This is a remarkable time for the medical cannabis industry internationally, with regions such as Latin America representing a large addressable market potential. This is similar to the market potential of Canada 5 years ago. I personally look forward to deploying my extensive expertise and relationships to help develop Khiron's capital market activities. I am delighted to take on this role and work with the accomplished team members of the Company."
Mr. Naprawa brings extensive institutional capital markets experience to the Company. Prior to joining Khiron, Mr. Naprawa was Partner at Sprott Capital Partners, Head of Equity Sales at Macquarie Canada, Head of Equity Sales and Trading at Dundee Securities, and Managing Director at Primary Capital. He was also previously founder and CEO of Startcast Solutions, a company successfully sold to a large telecommunications company. Mr. Naprawa holds a Bachelor of Arts from Queen's University.
Khiron also announced the grant of 200,000 stock options to Mr. Naprawa pursuant to Khiron's stock option plan, exercisable at a price of $1.40 per common share. The stock options have a term of 5 years and will vest in quarterly installments over a two-year period after shareholder approval of the Company's stock option plan at its annual general meeting.
About Khiron Life Sciences Corp.
Khiron is a Canadian integrated medical cannabis company with its core operations in Colombia, and is fully licenced in Colombia for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. Khiron combines leading international scientific expertise, agricultural advantages, and branded product market entrance experience to address the unmet medical needs in a market of over 620 million people in Latin America.
Further information on Khiron Life Sciences can be found at www.khiron.ca.
This press release may contain certain forward-looking information and statements ("forward-looking information") within the meaning of applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking information in this press release are reasonable, such forward-looking information has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron's control, including the risk factors discussed in Khiron's Filing Statement which is available on Khiron's SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
SOURCE Khiron Life Sciences Corp.
For further information: Darren Collins, Chief Financial Officer, T: +1 (705) 527-3564, E: [email protected]; Canada Investor Relations: Nicole Marchand, GRIT Capital, T: +1 (416) 428-3533, E: nmarchand[email protected]; U.S. Investor Relations: Lisa Wilson, In-Site Communications, Inc., T: +1 (917) 543-9932, E: [email protected]